Your Search Returned 30 tagged news reports
Genentech Inc. and partner Biogen Idec Inc. said Wednesday the Food and Drug Administration has asked for more information before considering approving Rituxan as a leukemia treatment. The drug is already approved as a treatment for rheumatoid arthritis...
Tags: Biogen Idec Inc., U.S. Genentech, Genentech Inc., FDA, United Kingdom, Cambridge, Rituximab, Genentech, Lymphoid leukemia, Lymphoma, Pharmaceutical companies, Monoclonal antibodies, Biogen Idec, Health Medical Pharma
Google Inc. said Monday that Arthur Levinson has resigned from the Internet search leader's board, averting a potential showdown with government regulators over his overlapping job as a director for computer and gadget maker Apple Inc. Images More Business...
Tags: Google Inc., Google and Apple Inc, Arthur Levinson, Apple Inc., Arthur D. Levinson, Mr. Levinson, Genentech Inc., Federal Trade Commission, google boards, Apple Eliminate
Facebook Inc. announced it hired David Ebersman, former chief financial officer of biotech company Genentech Inc. as the social network's new chief financial officer. In an interview, Mr. Ebersman, 39 years old, said he planned to focus on further expanding...
Tags: David Ebersman, financial officer, CFO of Genentech, chief financial, Genentech Inc., Palo Alto, Mr. Ebersman, IPO, social network, Roche Holding AG
Apple and Google share two directors: Eric Schmidt, the chief executive of Google, and Arthur Levinson, the former chief executive of Genentech. The Clayton Antitrust Act of 1914 prohibits a person's presence on the board of two rival companies when it...
Tags: Google and Apple, Apple and Google, US Federal Trade Commission, Eric E. Schmidt, Arthur Levinson, Genentech Inc., New York Times, Apple Inc, FTC, Google Inc
Genentech Inc., which was acquired by Roche Holding AG last month, announced Wednesday a phased voluntary withdrawal of psoriasis drug Raptiva from the U.S. market due to its link to a brain infection. Raptiva has been associated with an increased risk...
Tags: Genentech Withdraws Raptiva, Genentech Inc., U.S, Roche Holding AG, psoriasis drug, multifocal leukoencephalopathy, progressive multifocal, brain infection, fatal brain, drug raptiva
Swiss pharmaceutical giant Roche said Thursday it has completed its $46.8 billion takeover of California-based biotech firm Genentech. Roche, which already held 55.7 per cent of Genentech stock, said it acquired a further 37.5 per cent of shares by the...
Tags: Genentech Inc., Roche Holding AG, South San Francisco, roche completing, genentech share, giant roche, tender offer, genentech stock, drug giant, U.S
Having all but clinched a $46.8 billion deal to acquire the rest of Genentech Inc., Swiss pharmaceutical giant Roche Holding AG faces a potentially bigger challenge: How to integrate and squeeze value out of the pioneering California-based biotech firm...
Tags: Genentech Inc., Roche Holding AG, pharmaceutical giant, Swiss, giant roche, genentech deals, billions deals, U.S, biotech group
Roche Holding AG's negotiations to acquire South San Francisco-based Genentech Inc. are being held up by a legal debate over how long Roche will have to leave its tender offer open to shareholders before completing the deal, said a person familiar with...
Tags: Genentech Inc., Roche Holding AG, Biogen Idec, offer open, lupus nephritis
Swiss drug developer Roche boosted its hostile tender offer for biotechnology pioneer Genentech Inc. to $93 per share Friday, raising the total offer value to $45.7 billion, after its initial offer failed to pick up much support from shareholders. For...
Tags: Roche, Genentech Inc.
Roche increased its offer to buy the 44 percent of Genentech it does not already own by 7.5 percent late on Friday and reiterated it was confident of a successful conclusion to the drawn-out takeover battle. "We consider the offer price to be adequate.
Tags: Roche-Genentech, Genentech Inc, Genentech Stock Jumps, Roche Holding AG, Wall Street Journal, takeover battle, successful conclusion, share deal, source familiar